Thursday, July 27, 2006

New Stem Cell Lines

New Stem Cell Lines

Nature ran a story yesterday about the creation of four new stem cell lines—in two versions—by a biotechnology firm in Singapore. They have been made specifically for clinical use, because many of the existing research lines are not suitable for any developed therapies, and contain no non-human cells. The biotech firm will sell one version to researchers and will sell the other version at a higher cost and with negotiated royalties and so on. The article also reports that, in a different approach, a California firm has been cultivating its stem cells on an animal-free medium in order to purify them.

A Lawyer’s Viewpoint on the Veto

A Lawyer’s Viewpoint on the Veto

A publication of the University of Pittsburgh Law School, The Jurist, ran an interesting column (for those of you who follow legal affairs) about the stem cell research funding bill veto and its Constitutionality (or lack thereof). Some of the comments on it indicate that readers do not all agree with the writer (Elizabeth Price Foley of Florida International University College of Law) about the legal issue, but here are some notable excerpts:

“The Constitution, as interpreted by the U.S. Supreme Court for the last thirty-three years, does not recognize pre-viable embryos as “human life.” Although there has been fierce continuing debate about when constitutionally cognizable life begins, the law has remained essentially unchanged since the 1973 decision in Roe v. Wade, when the Court declared that “the word ‘person,’ as used in the Fourteenth Amendment, does not include the unborn.”

“We have, in short, a constitutional right to decide whether we want to bear or beget children. And there is no such thing, constitutionally speaking, as a pre-viable “child.””

“when a President vetoes a law because he disagrees with the constitutional rights the law acknowledges, he violates his oath of office and assumes near dictatorial power over both the legislative and judicial branches. By vetoing the stem cell bill, President Bush was not preserving, protecting, and defending our Constitution: he was giving it the finger.”

According to the brief bio at the end of the column, Foley “was formerly a member of the National Academy of Science’s Committee on Stem Cell Guidelines.” Which qualifies her to say a hell of a lot more about this than me…

I think this is an interesting way to approach the veto, particularly coming on the heels of an ABA (American Bar Association) panel that concluded the Bush administration is eroding the separation of powers between the legislative and executive branches. (One report is on CNN.) Seen in this way, the stem cell veto becomes not just an issue for science but also for jurisprudence, American democracy, and frankly, for all citizens. If a president can veto a constitutional bill on the basis of personal moral feelings, that sets a really bad precedent for the president as representative of the people. The next president, whether liberal or conservative, could do the same with a bill that has more immediate implications. This was at least just a limit on funding and not on the research itself—but that could come next.

I would love to see a research university sue the government on these grounds. If corporations can file suit when federal regulations on the environment are not in their favor, scientists should do the same.

California News Bit

California News Bit

The San Jose Mercury News had a story on Tuesday about biotech executives and the CIRM. Essentially, the story told what some of the biotech companies are nervous about. The first is, of course, the lawsuits against the CIRM and what will happen if they are held up; people understandably don’t want to put money into something as yet unauthorized by the court. Another issue is the sharing of profits. Although the biotech firms reached an agreement with the CIRM last week that they would retain patent rights to their discoveries/inventions, the CIRM is still considering a proposal which would require companies that make profits on CIRM-funded work to return some of that profit to the states. A third reason is that biotech is a generally risky business, and venture capitalists are hesitant about supporting it in the first place. There was also a feeling that $3 billion would not be enough money, and that one effective use of the CIRM—once the legal situation is over—would be to try to get private companies and donors to match or exceed the capital from the state.

This reminds me of something I read this week from Jonathan Alter of Newsweek:

But the $3 billion California voters approved in 2004 has been tied up in lawsuits; so far, only $12.1 million has been spent. And even when more money is released, much of it will be wasted creating duplicative labs, because no lab that receives federal financing can take part in embryonic-stem-cell research.

The waste he speaks of is shameful for the United States. It’s the US government and American citizens that are going to be the loser here.